Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease. Selectively ablating senescent cells using dasatinib plus quercetin (DQ)...

Full description

Saved in:

Bibliographic Details
Published in:	EBioMedicine Vol. 40; pp. 554 - 563
Main Authors:	Justice, Jamie N., Nambiar, Anoop M., Tchkonia, Tamar, LeBrasseur, Nathan K., Pascual, Rodolfo, Hashmi, Shahrukh K., Prata, Larissa, Masternak, Michal M., Kritchevsky, Stephen B., Musi, Nicolas, Kirkland, James L.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01.02.2019 Elsevier
Subjects:	Advanced Basic Science Aging Cellular senescence Clinical trial Idiopathic pulmonary fibrosis Internal Medicine Interstitial lung disease Research paper Senolytics Translation Translation Idiopathic pulmonary fibrosis Cellular senescence Aging Clinical trial Senolytics Interstitial lung disease
ISSN:	2352-3964, 2352-3964
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!